Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 12/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 12/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30359034 | 0.92 | MGLL (0.44) | MGLLKCNK3KCNK9HTR2AHTR2C | |
| SCHEMBL30359079 | 0.89 | MGLL (0.47) | MGLLKCNK3KCNK9HTR2AHTR2C | |
| SCHEMBL30359007 | 0.86 | MGLL (0.45) | MGLLKCNK3KCNK9HTR2AHTR2C | |
| SCHEMBL30359006 | 0.84 | KCNH2 (0.39) | MGLLKCNK3KCNK9HTR2CHTR2B | |
| SCHEMBL22001648 | 0.82 | KCNK3 (0.45) | MGLLKCNK3KCNK9 | |
| SCHEMBL30359125 | 0.81 | KCNK3 (0.41) | KCNK3KCNK9HTR2AHTR2CHTR2B | |
| SCHEMBL30359003 | 0.80 | HTR2A (0.42) | KCNK3KCNK9HTR2AHTR2CHTR2B | |
| SCHEMBL30359053 | 0.79 | KCNK3 (0.42) | KCNK3KCNK9HTR2AHTR2CHTR2B | |
| SCHEMBL21904749 | 0.78 | KCNK3 (0.48) | MGLLKCNK3KCNK9 | |
| SCHEMBL20070578 | 0.76 | MGLL (0.45) | MGLLKCNK3KCNK9ALOX5RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116057057-A | Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea | 拜耳公司 | 2023-05-02 | — | — | CN | disclosed |